Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis

Alan D. Salama

1UCL Department of Renal Medicine, Royal Free Hospital, London, United Kingdom

Clinical relapses are common in anti-neutrophil cytoplasm antibody (ANCA)–associated vasculitis, necessitating repeated treatment with immunosuppressive therapy, and increasing the risks of severe adverse events. Better understanding the basis of relapse would help stratify patients, testing the notion that more treatment may prevent development of relapse, whereas in those at low risk of disease flares, treatment minimization may be appropriate, reducing risks of adverse events, most notably infectious complications and drug toxicity. However, relapse can only occur following remission, and although defining clinical remission may seem straightforward, there is evidence in many remission patients of persistent inflammatory and immunological activity, at levels above those found in healthy individuals. This suggests that we may not truly be achieving disease remission in many patients and these persistent responses may set the patient up for subsequent disease flares. Understanding the underlying pathophysiological basis of disease activity and remission is paramount to help define better biomarkers of relapse, which should positively affect adverse events and patient outcomes.

Kidney Int Rep (2020) 5, 7–12; https://doi.org/10.1016/j.ekir.2019.10.005
KEYWORDS: ANCA; relapse; vasculitis
© 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Relapsed. A deterioration in a patient’s condition after a partial or apparently complete recovery; return of a disease, symptom, etc., after an interval of recovery.

—Oxford English Dictionary

ANCA-associated vasculitis, like many autoimmune diseases in which exposed autoantigens persist, follows a relapsing and remitting course, although the disease pattern for individual patients even with similar ANCA subtypes can be extremely variable. Certain susceptibility factors for relapse have been well established, such as proteinase-3–ANCA and clinical features of granulomatosis with polyangiitis; however, we have made few inroads into understanding what the pathophysiological drivers of relapse are, and why they are so different in patients with different ANCA subtypes. In part this is because, although overt disease flare may be clinically and immunologically obvious, subtle immune disease activity may be frequently missed. This subclinical inflammation brings into question what we mean by, and how we define, remission, which is generally based on clinical features, whereas more sensitive immunological or inflammatory phenotypes are not considered. We have introduced scoring systems, such as the Birmingham Vasculitis Activity Score and Birmingham Vasculitis Activity Score for Wegener’s granulomatosis, which suggest that disease is in remission when the score is zero, but we cannot always easily differentiate active disease from damage, which means we may not score some features that may portend ongoing inflammation after certain time points. Persistent or mild hematuria, subtle elevations in creatinine, or some ear, nose, and throat symptoms may be related to scarring or active disease and may not be recorded as active or persistent disease in these scoring systems. This may be appropriate, as we now realize that it can take many months for these symptoms or parameters to normalize; however, it emphasises that we need more sensitive biomarkers to inform us of when disease is truly suppressed or switched off.

For relapse to occur, first there must be remission, and although we know when patients are overtly not in remission, because of ongoing signs and symptoms, it is fair to say we do not have robust definitions of when they really have achieved remission. Using an analogy of an iceberg to represent disease (Figure 1), there may...
be a large part of the iceberg that is not visible above the water surface, which could represent the subclinical inflammation defined by various biomarkers, which may persist as overt clinical disease, slowly declines, and patients achieve clinical remission. Some persistent inflammation may result in symptoms that could be interpreted as being due to disease or damage, such as persistent crusting or epistaxis in granulomatosis with polyangiitis, whereas in some cases persistent inflammation may produce no overt clinical signs at all. Conversely, there are some patients who have clearly switched their disease off, and using a variety of parameters show immunological “normality,” behaving like healthy individuals. How we measure and define remission will inform us of relapse. For the moment, we are still reliant on clinical parameters, and clear markers of active inflammation, such as elevated levels of C-reactive protein, fibrinogen, and platelets, that are inadequate for optimal customization of therapies.

**Known Risk Factors for Relapse**

It has been a consistent finding from varied cohort studies and clinical trials that that being cytoplasmic-ANCA or proteinase-3–ANCA positive$^{1,2}$ rather than perinuclear-ANCA or myeloperoxidase-ANCA positive was a significant risk for relapsing disease (Table 1). In keeping with the immunological phenotype, patients with granulomatosis with polyangiitis have more clinical relapses than patients with microscopic polyangiitis, as do those with involvement of the lungs, upper airways,$^1$ or cardiovascular system.$^{2,3}$ In addition, higher levels of renal function$^2$ and carriage of nasal *Staphylococcus aureus*$^4$ appear to confer greater relapse risk, and this is true in both European and Chinese populations.$^{3,5}$ In some cohort studies, persistent ANCA positivity at the time of switching from induction to maintenance therapy is associated with an increased risk of future relapse,$^6$ whereas previous relapses are themselves risk factors for subsequent relapses. Disappointingly, apart from some histological features (including proportion of sclerosed glomeruli and lack of interstitial infiltrates),$^7$ there are no clear, clinically useful, predictors for renal relapse, which is associated with progression to end-stage renal disease. Importantly, rates of renal relapse, unlike other outcomes in ANCA-associated vasculitis, have remained relatively constant.$^8,9$ Interestingly, progression to end-stage renal disease occurs more frequently without overt renal relapses, which may highlight our inadequacies in diagnosing ongoing renal inflammation that may underlie some of what we term chronic kidney disease progression in patients with ANCA-associated glomerulonephritis.$^7$

Supporting the idea that persistent inflammation promotes some of the progression are data from the Chronic Renal Insufficiency Cohort (CRIC) study that demonstrate more rapid progression of chronic kidney disease (of various causes) in patients with markers of inflammation, such as elevated levels of circulating proinflammatory cytokines (tumor necrosis factor-$\alpha$) and fibrinogen and lower levels of albumin.$^{10}$

**Table 1. Recognized risk factors for relapse in ANCA-associated vasculitis**

| Disease parameters | Management parameters |
|--------------------|-----------------------|
| 1. PR3-ANCA | 1. Early drug withdrawal at 1 year |
| 2. GPA disease | 2. Induction therapy type; see Table 2 |
| 3. Higher presenting eGFR | 3. Maintenance therapy type; see Table 2 |
| 4. *Staphylococcus aureus* nasal carriage | 4. Antibiotic prophylaxis with co-trimoxazole |
| 5. ANCA positivity at time of completion of induction therapy | |
| 6. Previous relapses | |

ANCA, anti-neutrophil cytoplasm antibody; eGFR, estimated glomerular filtration rate; GPA, granulomatosis with polyangiitis; PR3, proteinase 3.

**Not All Remissions Are Created Equal: Rates of Relapse**

Modern induction regimens are generally very effective at producing disease remission, but which drug is used and which maintenance regimens patients are switched to, are more variable in the ability to maintain it. This tells us that there may be different aspects of the
immune response that are regulated by particular drugs, or they may do so more or less effectively. Various cohort studies and long-term follow-up of international trials have demonstrated relapse rates that vary between 21% and 89% at 5 years, depending on the induction and maintenance regimens that were used (Table 2). More recent trials have suggested that rates can be brought down to as low as 5% at 2 years with use of rituximab, which appears to be a significant improvement compared with previous rates (Table 2).

Induction with either oral cyclophosphamide or rituximab (and glucocorticoids) results in similar relapse rates, but these are greater if intravenous pulsed cyclophosphamide, or methotrexate, are used compared with oral cyclophosphamide, while pulsed cyclophosphamide results in fewer relapses than mycophenolate mofetil induction. However, in addition to which drug is used, the duration of treatment is critical. For example, in the NORAM trial, treatment with either cyclophosphamide or methotrexate was equally effective at inducing remission; however, after 1 year of treatment, cessation of drug was accompanied by significantly higher relapse rate in patients treated with methotrexate. Similarly, maintenance therapy with azathioprine is associated with less risk of early relapse than use of mycophenolate, whereas rituximab maintenance was more effective at preventing relapse than azathioprine. We have not understood what underlies these differences, and uncovering pathways that are variably effected by these various drugs may give us a clue as to what may provoke relapse. In addition, it is unclear how particular maintenance therapy prevents relapse, as there are mixed data suggesting that shorter or longer duration of therapy may be associated with increased or no difference in rates of relapse.

**Table 2.** Relapse rates in recent ANCA-associated vasculitis trials

| Trial          | Compared   | Results                        | Rates of relapse                  | Reference |
|----------------|------------|--------------------------------|-----------------------------------|-----------|
| CYCAZAREM      | CYP vs. CYP/AZA | Same relapse                  | 15.5% vs. 13.7% at 1.5 yr, 52% vs. 36% at 8.5 yr | 11        |
| NORAM          | MTX vs. CYP  | Greater relapse MTX           | 89% vs. 81% at 5 yr              | 12        |
| CYCLOPS        | i.v. vs. ORAL CYP | Greater relapse with i.v. CYP | 39.5% vs. 20.8% at 5 yr          | 13        |
| WEGENT         | AZA vs. MTX  | Same relapse                   | 36% vs. 33% at 2 yr              | 14        |
| IMPROVE        | AZA vs. MMF  | Greater relapse with MMF       | 37.5% vs. 55.2% at 3 yr          | 15        |
| MAINRITSAN     | AZA vs. RTX  | Greater relapse with AZA       | 29% vs. 5% at 28 mo              | 16        |
| RAVE           | RTX vs. CYP/AZA | Same relapse                | 32% vs. 29% at 18 mo             | 17        |
| RITUXVAS       | RTX/CYP vs. CYP/AZA | Same relapse              | 42% vs. 36% at 2 yr              | 18        |

AZA, azathioprine; CYP, cyclophosphamide; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab. Trials in bold show significant benefit of one drug versus the other.

**ANCA and Relapsing Disease**

ANCA has been proposed as a marker of impending disease relapse since the early days of its introduction as a clinical test. It was shown to be of some value in a single cohort study of patients with renal disease, with an ANCA increase (of more than 200% in the prior 3 months by solid phase assay) giving a hazard ratio of more than 11 for subsequent relapse in the next 18 months, but was less predictive in those with non-renal disease. Persistent ANCA positivity or development of positivity following a negative test showed only modest predictive power in a recent meta-analysis, with the caveat that this contained heterogeneous studies with variable testing strategies. However, using the RAVE dataset, increase titer (doubling of value or reaching an absolute level if previously negative) of proteinase-3–ANCA, by enzyme-linked immunosorbent assay, was clearly associated with subsequent disease flare, but only in those treated with rituximab, with a hazard ratio of 7.9 in those with kidney involvement. There were additional differences in the strength of association depending on the type of enzyme-linked immunosorbent assay used. In addition, in a prospective Japanese cohort, reappearance of myeloperoxidase-ANCA, by enzyme-linked immunosorbent assay, was clearly associated with subsequent disease flare, but only in those treated with rituximab, with a hazard ratio of 26 (95% confidence interval, 8.2–101.0), whereas ANCA persistence was not associated with higher rates of relapse. Differences in myeloperoxidase-ANCA epitope specificity have been reported between acute disease and remission, suggesting there may be differences in antibody pathogenicity that could potentially explain ANCA persistence and clinical disease remission in some patients. Standard ANCA measurements during remission remain a feature of clinical practice for many physicians and rising titers may warrant more careful follow-up, but it remains controversial whether that should result in immediate change of therapy.

**Subclinical Inflammation and Predicting Relapses**

It is clear that many inflammatory pathways are engaged at the time of disease activity and relapse, and some of these never return to normality (seen in
healthy controls) during remission,\textsuperscript{30,31} suggesting that they may be the subclinical factors driving relapse. Therefore, either there is a baseline abnormality in these pathways in patients compared with healthy individuals or the immunological pathways may remain turned on at lower levels without inducing overt disease. In part, our inability to predict relapse comes from the reliance on biomarkers that are poor at representing the subclinical inflammation that occurs (Figure 1), such as creatinine, proteinuria, and hematuria in patients with renal disease.

An ideal biomarker to predict relapse in the near future would likely inform of how therapy may be tailored for the individual, minimizing exposure in those less likely to relapse and maintaining higher levels of therapy in those who have greater likelihood of disease flare (although we also need to prove that more treatment will prevent relapse). Optimally, this would be used at the time of disease presentation, during induction therapy or soon after, before deciding on maintenance therapy. Some markers have shown such associations, with variable positive predictive values in cohort studies, but the time lag to relapse may be protracted, meaning that augmented immunosuppression may be delivered to a significant number of individuals for a long period of time, increasing potential adverse events.

Many other biomarkers, including circulating levels of leukocyte subsets (such as B- or T-lymphocyte subsets),\textsuperscript{32,33} urinary lymphocytes, or urinary leukocyte proteins\textsuperscript{34-37} have been shown to be associated with disease activity, but none have validated as robust markers of subsequent relapse. The most promising biomarkers have been a CD8 T-cell subset that in a single-center study showed a strong association with subsequent relapse in patients with ANCA-associated vasculitis or systemic lupus erythematosus, which requires prospective validation.\textsuperscript{38} Another was changes in serum calprotectin levels, which increased while on therapy between baseline and month 3 or 6, in samples from the RAVE trial, again only in those treated with rituximab (like the predictive ability of proteinase-3–ANCA).\textsuperscript{39} This suggests that differences exist in suppression of various inflammatory pathways when using different induction regimens, despite similar clinical remission rates, highlighting again that clinical remission is not telling us everything about underlying disease pathway suppression. Perhaps unsurprisingly, since the change in calprotectin was not predictive of relapse in cyclophosphamide-treated patients from RAVE, no association with relapse was found using samples from the MYCYC (mycophenolate vs cyclophosphamide) trial (unpublished data). These data suggest that other biomarkers or combinations of biomarkers could be found that should allow us to predict future disease relapse.

Finally, there are those patients demonstrating prolonged disease-free remission\textsuperscript{40} who have become ANCA negative and remain off all immunotherapy, including glucocorticoids, who may truly have switched off all of the subclinical inflammatory and immunological pathways, with some evidence that some of their regulatory cell subsets are numerically restored to levels found in healthy individuals (Oates T, Flores-Barros F, Todd SK, et al. Restablishment of immune tolerance in ANCA-associated vasculitis: a cohort with both sustained undetectable antibody, and disease free remission [abstract]. \textit{J Am Soc Nephrol}. 2016;27:282). This group of patients may provide some clues as to what pathways underpin the subclinical inflammation and predisposition to relapse.

Other Considerations in Relapse Studies

One issue that is not discussed in studies comparing i.v. and oral therapies is compliance with the oral regimen, which can be suboptimal, with rates of noncompliance in many chronic rheumatological diseases estimated at more than 50% and as high as 82%.\textsuperscript{41} Although specific data for ANCA-associated vasculitis is lacking, this may be an issue especially in maintenance studies. Assessment of compliance through drug monitoring where possible may help in this regard.

In addition, it is worth considering that unblinded trials of therapy withdrawal may be hindered by the risk of bias in defining a clinical event as a disease relapse if it is known that the patient is not on treatment, rather than a transient infection, for example.

Future studies defining optimal regimens and duration of treatments should consider these issues, by potentially blinding physicians to treatments, using hard (inflammatory or immunological) endpoints, and making attempts at confirming compliance.

Summary

We still rely on clinical definitions of remission and these are not clear-cut or uniform. We need better, more granular inflammatory and immunological profiles to really understand disease states. These should provide better markers of disease quiescence, activity, and potentially markers that can predict short- or long-term relapse. Only then will we be able to truly customize therapy for individual patients, minimizing risks of adverse events by appropriately reducing therapies in some, and reducing risks of relapse in others by appropriately augmenting therapies.
The author declared no competing interests.

REFERENCES

1. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908–2918.

2. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542–548.

3. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, et al. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49:2181–2190.

4. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12–17.

5. Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol. 2014;66:1920–1926.

6. Morgan MD, Szeto M, Walsh M, et al. Negative antineutrophil cytoplasmic antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther. 2017;19:129.

7. Goceoglu A, Berden AE, Fiocco M, et al. ANCA-associated glomerulonephritis: risk factors for renal relapse. PLoS One. 2016;11:e0165402.

8. Rhee RL, Hogan SL, Poulton CJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol. 2016;68:1711–1720.

9. Wester Trejo MAC, Flossmann O, Westman KW, et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology (Oxford). 2019;58:103–109.

10. Amdur RL, Feldman HI, Gupta J, et al. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2016;11:1546–1556.

11. Jayne D, Rasmussen N, Andrass K, et al. A randomized trial of maintenance therapy for vasculitis associated with anti-neutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.

12. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–2469.

13. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–680.

14. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–2803.

15. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381–2388.

16. Guillemin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–1780.

17. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232.

18. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.

19. Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78:399–405.

20. de Joode AAE, Sanders J, Puechel X, et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology (Oxford). 2017;56:1894–1901.

21. Sanders JS, de Joode AA, Desseaux RG, et al. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrol Dial Transplant. 2016;31:1453–1459.

22. Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1662–1668.

23. Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990;336:709–711.

24. Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2015;26:537–542.

25. Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology (Oxford). 2012;51:100–109.

26. Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68:1700–1710.

27. Watanabe H, Sada KE, Matsumoto Y, et al. Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol. 2018;70:1626–1633.

28. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123:1773–1783.

29. Free ME, Stember KG, Hess J, et al. Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis [e-pub ahead of print]. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.102306. Accessed November 24, 2019.
30. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. *Nephrol Dial Transplant*. 2010;25:2209–2217.

31. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. *Ann Rheum Dis*. 2006;65:1484–1489.

32. Morgan MD, Day CJ, Piper KP, et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. *Immunology*. 2010;130:64–73.

33. Bunch DO, McGregor JG, Khandooibhai NB, et al. Decreased CD5(+)- B cells in active ANCA vasculitis and relapse after rituximab. *Clin J Am Soc Nephrol*. 2013;8:382–391.

34. Abdulahad WH, Kallenber CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2009;60:2830–2838.

35. de Souza AW, Abdulahad WH, Sosicka P, et al. Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? *Clin Exp Immunol*. 2014;178:270–278.

36. O'Reilly VP, Wong L, Kennedy C, et al. Urinary soluble CD163 in active renal vasculitis. *J Am Soc Nephrol*. 2016;27:2906–2916.

37. Tam FW, Sanders JS, George A, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. *Nephrol Dial Transplant*. 2004;19:2761–2768.

38. McKinney EF, Lyons PA, Carr EJ, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. *Nat Med*. 2010;16:586–591, 1p following 91.

39. Pepper RJ, Draibe JB, Caplin B, et al. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheumatol*. 2017;69:185–193.

40. Hogan SL, Nachman PH, Poulton CJ, et al. Understanding long-term remission of therapy in antineutrophil cytoplasmic antibody-associated vasculitis. *Kidney Int Rep*. 2019;4:551–560.

41. Campbell NKJ, Saadeldin K, De Vera MA. The duality of economic issues with medication non-adherence in patients with inflammatory arthritis. *Curr Rheumatol Rep*. 2017;19:66.